Aclarion, Inc. ACON

Aclarion adds University of Arizona College of Medicine – Phoenix as a CLARITY trial site. New CLARITY trial site expands clinical validation efforts for Aclarion's core technology.

Aclarion receives notice of allowance for patent advancing accuracy and adoption of Nociscan's MR Spectroscopy scan process. Patent strengthens protection for core Nociscan MRS technology potentially enhancing competitive position and adoption.

Aclarion partners with PRIA Healthcare to advance reimbursement and commercial adoption of its AI-powered Nociscan platform. Partnership targets reimbursement gains essential for Nociscan platform commercialization and revenue growth.

Aclarion rejected Echo Lake Capital's unsolicited acquisition proposal. Rejection of acquisition offer may shift short-term investor sentiment and valuation views.

Aclarion adds Institute of Neuro Innovation to support Nociscan growth and real-world evidence generation. Addition expands Nociscan adoption and evidence base with moderate effect on Aclarion operations.

Aclarion technology demonstrates potential beyond surgical planning according to new immune-biomarker study results. New study expands applications of Aclarion technology which may moderately improve market perception and future positioning.

Echo Lake Capital offers to acquire Aclarion Inc. (ACON). Acquisition offer constitutes a major strategic move likely to alter Aclarion's ownership structure and market trajectory.

Aclarion, Inc. issued a response to Echo Lake Capital’s letter and unsolicited proposal regarding the company. Unsolicited proposal from Echo Lake Capital raises possibility of ownership or strategic shifts at Aclarion.

Aclarion (ACON) stock receives a Buy rating upgrade from analysts. The change reflects improved company outlook and growth potential in its core medical technology operations. Analyst Buy upgrade for ACON can moderately lift near-term investor interest and share price without altering long-term fundamentals.

Aclarion, Inc. (ACON) reported a Q1 net loss and missed revenue estimates. Q1 loss and revenue miss highlight financial underperformance with moderate impact on market sentiment and trajectory.

Aclarion, Inc. (ACON) added its first private practice site in Los Angeles to the CLARITY Trial to accelerate enrollment. Adding the first private practice site to the CLARITY Trial accelerates enrollment and supports progress toward clinical validation.

Aclarion, Inc. (ACON) announced its second commercial agreement with Weill Cornell Medicine, expanding partnerships for its precision neuroimaging technology. Second commercial agreement with prestigious Weill Cornell Medicine boosts validation, adoption, and revenue potential for Aclarion.

Aclarion, Inc. (ACON) reported strong Q1 2026 results featuring 196% annual scan volume growth, reflecting accelerating clinical adoption. 196% scan volume growth signals accelerating clinical adoption, positioning Aclarion for significant revenue expansion and improved market performance.

Aclarion, Inc. (ACON) announced a $2.5 million stock repurchase plan. Stock repurchase plan signals management confidence and may positively influence financial metrics and investor sentiment without fundamentally altering operations.

Aclarion, Inc. (ACON) secures U.S. patent for scalable, AI-driven assessment of chronic low back pain. Patent protects core AI technology for chronic back pain assessment, strengthening IP and enabling scalable commercialization.

Aclarion, Inc. (ACON) announces agreement with Weill Cornell Medicine. Agreement with Weill Cornell Medicine is a major strategic partnership boosting Aclarion's research credibility and commercialization prospects.

Aclarion highlights growing adoption of its Nociscan technology at The London Clinic through a new physician testimonial video. Growing Nociscan adoption at a prominent clinic like The London Clinic validates the technology and could positively influence market sentiment and sales trajectory.

Echo Lake Capital demands the resignation of David Neal from Aclarion Inc.'s board of directors. Activist investor call for board resignation introduces governance pressure with moderate potential to sway investor sentiment and company leadership.

Aclarion, Inc. (ACON) published a CEO shareholder letter highlighting strategic progress and key 2026 catalysts. CEO letter outlines strategic progress and 2026 catalysts likely to significantly influence Aclarion's trajectory and investor sentiment.

Aclarion, Inc. (ACON) adopted a one-year limited duration stockholder rights plan, triggering if any person or group acquires 15% or more of its common stock without board approval, diluting such ownership to protect other shareholders. Stockholder rights plan adoption signals vulnerability to activism or takeovers, moderately influencing investor sentiment and governance perceptions.

Aclarion, Inc. has published its 2026 shareholder letter from the Chairman, outlining the company's strategic vision and operational updates. The letter emphasizes Aclarion's commitment to innovation and growth in the healthcare sector, detailing recent achievements and future goals. Shareholders are encouraged to engage with the company's progress as it navigates market challenges and opportunities. The shareholder letter indicates a focus on strategic growth and innovation, which may moderately influence investor sentiment and operational performance.

Aclarion, Inc. has acquired Source Healthcare, a high-volume practice, to enhance the growth of its Nociscan product and bolster real-world evidence generation. This strategic move aims to expand Aclarion's capabilities in providing valuable insights and data to support its offerings in the healthcare market. The acquisition of Source Healthcare is a significant strategic move that is expected to enhance Aclarion's market position and product offerings.

Aclarion, Inc. has successfully strengthened its balance sheet and extended its cash runway into 2028, indicating improved financial stability and operational longevity. This strategic move is expected to support the company's growth initiatives and enhance its market position. Extending the cash runway significantly impacts Aclarion's ability to execute strategic initiatives and maintain operations without immediate financial pressure.

Aclarion, Inc. provided an update on its 2025 performance and outlined its corporate outlook for 2026, highlighting strategic initiatives and anticipated growth in key areas. The company aims to enhance its market position and drive innovation in its offerings, focusing on expanding its customer base and improving operational efficiencies. Significant strategic initiatives and growth plans are expected to impact Aclarion's future performance and market position.

Aclarion, Inc. (ACON) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This increased activity may reflect broader market trends or specific developments related to the company, potentially influencing its stock performance and investor sentiment. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Aclarion, Inc. has announced the enrollment of the first patients at two additional sites for its CLARITY trial, which aims to evaluate the effectiveness of its technology in diagnosing and treating chronic pain. The company provided guidance on the expected timeline for the availability of initial data from the trial, indicating progress in its clinical research efforts. The expansion of the CLARITY trial and the forthcoming data could moderately influence Aclarion's market position and investor sentiment.

Aclarion, Inc. announced the publication of a research article on Nociscan in a special pain issue of the International Journal of Spine Surgery (IJSS). The article highlights the potential of Nociscan in improving the diagnosis and treatment of chronic pain conditions. This publication is expected to enhance awareness and understanding of Nociscan's applications in spine surgery and pain management. The publication of the research article may moderately influence Aclarion's market position and product awareness in the pain management sector.

Aclarion, Inc. has appointed Jason Brosniak as Commercial Director to enhance adoption and market expansion efforts in the Eastern U.S. Brosniak brings extensive experience in the healthcare sector, aiming to drive growth and strengthen the company's presence in this region. The appointment of a new Commercial Director is expected to moderately influence Aclarion's market positioning and operational effectiveness.

Aclarion, Inc. has appointed Dan Isherwood as the UK Commercial Director to enhance the company's market presence and drive the adoption of its products in the UK. Isherwood brings extensive experience in the healthcare sector, aiming to leverage his expertise to expand Aclarion's reach and influence in the market. The appointment of a new commercial director is expected to moderately influence Aclarion's market positioning and operational effectiveness.

Aclarion, Inc. (ACON) has been awarded the 'Rising Star' title at the 2025 Digital Health Hub Foundation: Digital Health Awards during the HLTH conference. This recognition highlights Aclarion's innovative contributions to the digital health sector, positioning the company favorably within the industry. Winning a prestigious award enhances Aclarion's reputation and could significantly influence its market positioning and investor sentiment.